Primary Immunodeficiency (PID)
ASCIA has significantly expanded its range of information for health professionals and patients on Primary Immunodeficiency (PID) since 2014, including the ASCIA Transplantation and PID (TAPID) Project, development of resources to support the use of subcutaneous immunoglobulin (SCIg) and a dedicated webpage www.allergy.org.au/immunodeficiency
TAPID 2018 Meeting
Saturday 5 to Sunday 6 May 2018
Larwill Hotel, Melbourne Australia
ASCIA TAPID Project
The ASCIA TAPID (Transplantation And PID) project is an important and ongoing collaboration between clinical immunologists, transplant physicians and international PID experts, facilitated by ASCIA.
TAPID meetings enable complex PID and transplantation cases to be discussed in a confidential expert forum.
Since the first TAPID face to face meeting was held in February 2014, the TAPID project membership has increased 5 fold, from 12 to more than 60 members and teleconferences are now held each month.
A TAPID face to face meeting was held in Melbourne in 2017 (20-21 May) and the 2018 meeting will also be held in Melbourne in May (5-6). At the May 2018 ASCIA TAPID meeting, as well as complex PID transplantation cases being presented by up to 40 delegates, a draft ASCIA TAPID publication will also be discussedThe main objective of the TAPID project is to have regular collaborations and discussions between immunologists and transplant physicians in major centres that transplant patients with PIDs in Australasia.
At the ASCIA PID (APID) Consultants Meeting in May 2013 the concept of the TAPID (transplantation and PID) project was initiated. Since then:
- TAPID face to face meetings with immunologists and transplant physicians have been held in February 2014 and May 2017.
- TAPID teleconferences have been held (almost monthly) since mid 2014.
This project has been supported by an unrestricted educational grant from CSL Behring.
ASCIA Immunodeficiency (ID) Register
The objectives of this project are to:
- Collect data on all patients with primary immune deficiency diseases in Australia and New Zealand.
- Enhance research, therapies and advocacy for primary and secondary immune deficiencies.
This project is supported by unrestricted educational grants from CSL Behring and Octapharma.
The estimated completion date for this project is mid 2018.
Updated May 2018